ETRA

Electra Therapeutics Inc

7.35

Nov 05 • 3:59 PM ET -0.62 (-7.78%)

7.35

Aftermarket • 5:57 PM ET +0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: ALXO ANAB ACRS ALMS CLDX XNCR UPB IMVT SYRE ABVX

| Held by: VTI VXF VTWO TMED VTWG VTWV VTHR

Index	-
Market Cap	461.33M
Enterprise Value	-
Income	-
Sales	-
Book/sh	-
Cash/sh	-
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 18, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	-
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.45
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	- -

Insider Own	38.62%
Insider Trans	17.51%
Inst Own	12.68%
Inst Trans	2.73%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.11%
SMA50	-24.52%
SMA200	-24.52%
Trades

Shs Outstand	62.77M
Shs Float	38.52M
Short Float	1.06%
Short Ratio	0.66
Short Interest	0.41M
52W High	15.50 -52.58%
52W Low	6.86 7.06%
Volatility	13.95% 9.80%
ATR (14)	0.94
RSI (14)	30.05
Beta	-
Rel Volume	0.86
Avg Volume	617.11K
Volume	528,995

Perf Week	-14.93%
Perf Month	-19.76%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-51.00%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	33.50
Prev Close	7.97
Price	7.35
Change %	-7.78%

Consensus

Strong Buy

Avg. Price Target

$33.50

Implied Upside

+355.8%

Analysts6incl. previous ratings

Rating Distribution6 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 26, 2026	Initiated	HH.C. Wainwright	Buy	$30	+308.2%
Oct 22, 2026	Initiated	JJP Morgan	Overweight	$36	+389.8%
Oct 13, 2026	Initiated	TTD Cowen	Buy
Oct 13, 2026	Initiated	JJefferies	Buy	$32	+335.4%
Oct 13, 2026	Initiated	EEvercore ISI	Outperform	$36	+389.8%
Oct 13, 2026	Initiated	CCantor Fitzgerald	Overweight

Nov-04-26 08:00AM	Electra Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference in London (GlobeNewswire)
Sep-30-26 08:23AM	Oura Shows How Shaky the IPO Market Really Is (Barrons.com)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GORDON CARL L	Director	Nov 03 '26	Buy	7.86	245,113	1,926,606	5,175,604	Nov 05 05:47 PM
GORDON CARL L	Director	Nov 05 '26	Buy	7.31	156,091	1,141,025	5,220,762	Nov 05 05:47 PM
GORDON CARL L	Director	Nov 04 '26	Buy	7.53	71,367	537,485	5,189,871	Nov 05 05:47 PM
ORBIMED ADVISORS LLC	Director	Nov 03 '26	Buy	7.86	245,113	1,926,606	5,175,604	Nov 05 05:39 PM
ORBIMED ADVISORS LLC	Director	Nov 05 '26	Buy	7.31	156,091	1,141,025	5,220,762	Nov 05 05:39 PM
ORBIMED ADVISORS LLC	Director	Nov 04 '26	Buy	7.53	71,367	537,485	5,189,871	Nov 05 05:39 PM
GORDON CARL L	Director	Sep 21 '26	Buy	15.00	1,333,333	19,999,995	5,126,891	Sep 23 05:35 PM
ORBIMED ADVISORS LLC	Director	Sep 21 '26	Buy	15.00	1,333,333	19,999,995	5,126,891	Sep 23 05:29 PM

Electra Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in therapies against novel targets for diseases in immunology and cancer. The company was founded by Adam Rosenthal on October 11, 2018 and is headquartered in South San Francisco, CA.

Pharm.D.Dr. Quehuong Dong M.B.A.

Chief Technology OfficerMr. Gary S. Koe Ph.D.

Ph.D.Dr. Kim-Hien Dao D.O.

Chief Financial OfficerMr. Christopher William Clark C.F.A.

Senior VP of Finance & Principal Accounting OfficerMr. David J. Tucker

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ETRA

Electra Therapeutics Inc

Upgrade your Finviz experience